TABLE 2.

OR (95% CI) values for diabetes complications by HSP27 values in the nested case-control study within the EURODIAB Prospective Complications Study

	OR (95% CI)	OR (95% CI)*	OR (95% CI)†
All complications
logHSP27	1.11 (0.95–1.31)	1.14 (0.95–1.36)	1.15 (0.93–1.43)
HSP27 (pg/ml)
<250.0	1.00	1.00	1.00
250.0–507.1	1.22 (0.72–2.07)	1.22 (0.66–2.23)	0.94 (0.45–1.97)
507.2–1,135.0	1.13 (0.67–1.92)	1.42 (0.78–2.60)	0.92 (0.44–1.95)
>1,135.0	1.42 (0.85–2.39)	1.55 (0.85–2.82)	1.31 (0.64–2.73)
P for trend	0.24	0.13	0.47
DSP
logHSP27	1.24 (1.04–1.49)	1.32 (1.06–1.63)	1.53 (1.16–2.02)
HSP27 (pg/ml)
<250.0	1.00	1.00	1.00
250.0–507.1	1.36 (0.74–2.50)	1.13 (0.54–2.39)	0.65 (0.24–1.74)
507.2–1,135.0	1.39 (0.76–2.54)	1.84 (0.89–3.82)	1.19 (0.46–3.10)
>1,135.0	1.94 (1.08–3.50)	2.13 (1.04–4.33)	2.27 (0.90–5.75)
P for trend	0.03	0.016	0.03
Micro-/macroalbuminuria
logHSP27	1.19 (1.00–1.42)	1.21 (0.98–1.41)	1.24 (0.92–1.68)
HSP27 (pg/ml)
<250.0	1.00	1.00	1.00
250.0–507.1	1.20 (0.66–2.18)	1.22 (0.58–2.55)	0.88 (0.31–2.52)
507.2–1,135.0	1.31 (0.72–2.37)	2.10 (1.02–4.32)	1.10 (0.38–3.16)
>1,135.0	1.68 (0.94–2.99)	1.92 (0.95–3.89)	1.56 (0.58–4.20)
P for trend	0.08	0.03	0.31
Retinopathy
logHSP27	1.13 (0.96–1.34)	1.15 (0.94–1.41)	1.16 (0.90–1.51)
HSP27 (pg/ml)
<250.0	1.00	1.00	1.00
250.0–507.1	1.15 (0.66–1.99)	1.21 (0.61–2.40)	0.98 (0.41–2.38)
507.2–1,135.0	1.23 (0.71–2.13)	1.94 (0.99–3.82)	1.35 (0.55–3.29)
>1,135.0	1.48 (0.87–2.54)	1.69 (0.86–3.31)	1.39 (0.58–3.34)
P for trend	0.15	0.06	0.34
CVD
logHSP27	1.13 (0.93–1.37)	1.18 (0.94–1.49)	1.10 (0.83–1.46)
HSP27 (pg/ml)
<250.0	1.00	1.00	1.00
250.0–507.1	1.43 (0.75–2.72)	1.86 (0.84–4.14)	1.22 (0.47–3.15)
507.2–1,135.0	1.25 (0.65–2.41)	1.83 (0.82–4.08)	1.09 (0.41–2.86)
>1,135.0	1.54 (0.81–2.91)	1.91 (0.86–4.24)	1.23 (0.48–3.16)
P for trend	0.28	0.16	0.74

^*Adjusted for age and diabetes duration.

^†Adjusted for age, diabetes duration, hypertension, A1C, smoking, and logTNF-α.